( A ) Seahorse XFe24 extracellular flux analyzer traces of a glycolysis stress test in caSMCs measured as the ECAR by sequential injection of 20 mM glucose, 1 M oligomycin, and 100 mM 2-deoxy-d-glucose (2-DG)

GLP-1 RAs help by: Decreasing pro-inflammatory cytokine levels Reducing the Psoriasis Area Severity Index (PASI) Improving insulin sensitivity and reducing obesity (both of which exacerbate psoriasis) Wound Healing: In diabetic patients and others with chronic wounds, GLP-1 medications improve healing by: Reducing harmful MMP-9 levels and improving MMP-9/TIMP ratios Enhancing angiogenesis (new blood vessel formation) Normalizing C-reactive protein (CRP) levels, a marker of systemic inflammation Multi-System Anti-Inflammatory Effects of GLP-1 Medications GLP-1 agonists exhibit systemic anti-inflammatory effects across multiple organ systems: Cardiovascular: Reduces arterial plaque, improves endothelial function Renal: Protects glomeruli, reduces proteinuria, slows kidney disease progression Pulmonary: Reduces airway inflammation, potential benefits in asthma and COPD Liver (NAFLD/NASH): Lowers hepatic inflammation, improves liver enzymes GI/Metabolic: Reduces markers like IL-6 and CRP

Contamination with other substances or inaccurate dosing are real concerns with non-pharmaceutical grade products
This may be beneficial for psoriasis patients and enhance skin health
Yes cortisol disrupts microbial balance, suppresses SCFAs, lowers GLP-1 signaling, and shifts metabolism toward fat storage